Reply: Disentangling ovarian reserve and embryo quality in vaginal progesterone effectiveness studies
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Dear Editors, We thank Peralta et al. (2026) for their thoughtful correspondence regarding our study. They raise the pertinent question of whether differences in embryo competence, proxied by ovarian reserve markers (anti-Müllerian hormone (AMH) and antral follicle count), could account for the superior outcomes observed in the vaginal oil capsule (Utrogestan®) group. We welcome the opportunity to address these points. While we acknowledge the baseline differences in age and ovarian reserve, we must emphasize that our analysis employed both multivariable regression and propensity score matching, adjusting for 12 distinct covariates. While the authors suggest that AMH adjustment cannot fully account for embryo quality, maternal age remains the most validated predictor of aneuploidy and embryo quality. By controlling for age and AMH simultaneously, we have accounted for the primary drivers of embryo competence known to date. Furthermore, we purposely reported adjusted risk ratios (aRRs) rather than odds ratios. As the primary outcomes (live birth and miscarriage) are common (>10%), Odds ratios tend to overestimate treatment effects. By using aRR, we have provided a more conservative and clinically realistic estimation of the effect size.
Fields of Study & Subjects
Assisted Reproductive Technology and Twin Pregnancy
Reproductive Biology and Fertility
Reproductive Health and Technologies
Publication details
- Journal / source
- Human Reproduction
- Volume
- 41
- Issue
- 6
- Pages
- 1015–1016
- Publication date
- 30 March 2026
- Language
- EN